Compare VENUS REMEDIES with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PLETHICO PHARMA VENUS REMEDIES/
PLETHICO PHARMA
 
P/E (TTM) x -1.1 -1.1 - View Chart
P/BV x 0.1 0.0 441.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PLETHICO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PLETHICO PHARMA
Mar-14
VENUS REMEDIES/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs126395 31.9%   
Low Rs6131 195.2%   
Sales per share (Unadj.) Rs301.8604.4 49.9%  
Earnings per share (Unadj.) Rs-24.932.5 -76.6%  
Cash flow per share (Unadj.) Rs2.551.3 5.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3473.6 61.9%  
Shares outstanding (eoy) m12.3434.08 36.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.4 87.9%   
Avg P/E ratio x-3.86.6 -57.3%  
P/CF ratio (eoy) x36.74.2 885.0%  
Price / Book Value ratio x0.30.5 70.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1547,262 15.9%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3931,596 24.6%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72420,598 18.1%  
Other income Rs m23386 5.8%   
Total revenues Rs m3,74720,984 17.9%   
Gross profit Rs m3952,818 14.0%  
Depreciation Rs m338642 52.7%   
Interest Rs m3541,593 22.2%   
Profit before tax Rs m-275969 -28.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-138 -22.8%   
Profit after tax Rs m-3071,107 -27.7%  
Gross profit margin %10.613.7 77.5%  
Effective tax rate %-11.5-14.3 80.3%   
Net profit margin %-8.25.4 -153.4%  
BALANCE SHEET DATA
Current assets Rs m2,63818,877 14.0%   
Current liabilities Rs m2,30511,896 19.4%   
Net working cap to sales %8.933.9 26.4%  
Current ratio x1.11.6 72.1%  
Inventory Days Days13536 376.9%  
Debtors Days Days46198 23.4%  
Net fixed assets Rs m4,8719,861 49.4%   
Share capital Rs m123341 36.2%   
"Free" reserves Rs m3,49612,331 28.3%   
Net worth Rs m3,61916,139 22.4%   
Long term debt Rs m1,3744,706 29.2%   
Total assets Rs m7,50933,146 22.7%  
Interest coverage x0.21.6 13.9%   
Debt to equity ratio x0.40.3 130.2%  
Sales to assets ratio x0.50.6 79.8%   
Return on assets %0.68.1 7.7%  
Return on equity %-8.56.9 -123.6%  
Return on capital %1.612.3 12.9%  
Exports to sales %021.4 0.0%   
Imports to sales %13.915.2 91.1%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs m5173,136 16.5%   
Fx inflow Rs m04,402 0.0%   
Fx outflow Rs m5173,184 16.2%   
Net fx Rs m-5171,219 -42.4%   
CASH FLOW
From Operations Rs m5142,437 21.1%  
From Investments Rs m-123-6,265 2.0%  
From Financial Activity Rs m-3872,490 -15.5%  
Net Cashflow Rs m4-1,337 -0.3%  

Share Holding

Indian Promoters % 32.9 82.7 39.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.3 4.2%  
FIIs % 0.6 5.5 10.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 7.5 885.3%  
Shareholders   20,121 10,665 188.7%  
Pledged promoter(s) holding % 36.4 85.7 42.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 17, 2019 01:51 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - J.B.CHEMICALS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS